TEST:

PD-L1 IHC 22C3 pharmDx

P3, N=336, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: Sep 2029 --> Sep 2032 | Initiation date: Jun 2026 --> Mar 2027 | Trial primary completion date: Sep 2029 --> Sep 2032

P=N/A, N=100, Recruiting, Naestved Hospital | Trial completion date: May 2023 --> Dec 2028 | Trial primary completion date: Mar 2023 --> Dec 2028

The results may reflect the utility of the expert led standardized protocol used to train pathologists for scoring PD-L1 staining in NSCLC specimens. The digital image-led training approach has the additional advantage of providing a computer-assisted scoring system and allows for remote training of pathologists worldwide.

P3, N=1170, Active, not recruiting, Daiichi Sankyo | Trial completion date: May 2029 --> May 2031

The patient achieved a PR after 3.1 months of nivolumab treatment, although disease progression was observed after 5 months. Although limited by its single-patient nature, this report suggests that PD-L1 gene amplification may represent complementary biological information associated with the efficacy of ICI rechallenge, warranting further investigation in larger cohorts.

P2, N=70, Recruiting, Innate Pharma | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2027

P1, N=30, Recruiting, University of Texas Southwestern Medical Center | Trial completion date: Apr 2026 --> Apr 2029 | Trial primary completion date: Apr 2026 --> Apr 2028

P3, N=740, Active, not recruiting, Daiichi Sankyo | Recruiting --> Active, not recruiting | Trial completion date: Apr 2028 --> Mar 2032 | Trial primary completion date: Feb 2028 --> Mar 2030

In this retrospective, single-center study, 86 patients with metastatic NSCLC treated with ICIs (pembrolizumab or atezolizumab) between January 2020 and December 2025 were included. While these results should be interpreted cautiously given the modest sample size and the small number of progression events, they are consistent with broader real-world evidence indicating that PD-L1 expression alone may not reliably stratify clinical benefit in metastatic NSCLC. Larger prospective studies integrating PD-L1 with complementary biomarkers are needed to confirm these observations.

Despite its high expression in advanced solid tumours, PD-L1 showed limited prognostic value in our cancer cohort. In contrast, systemic inflammatory markers particularly PLR, emerged as a potential indicator of clinical outcome. Our data suggest that integrating PD-L1 status with systemic inflammatory markers may improve outcome prediction and help inform therapeutic decision-making in patients with advanced malignancies.

P2, N=33, Terminated, NeoImmuneTech | N=83 --> 33 | Active, not recruiting --> Terminated; sponsor decision (not for safety)

PD-L1 expression may be associated with tumor grade in early-stage endometrioid endometrial cancer. However, its clinical significance remains unclear. These findings may be relevant in the context of fertility- preserving management and require further investigation.